ログイン
言語:

WEKO3

  • トップ
  • ランキング


インデックスリンク

インデックスツリー

  • RootNode

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 055 医学部附属病院
  2. 0551 学術論文

In Vitro Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod: Possible Mechanism of Iguratimod-Warfarin Interaction

http://hdl.handle.net/10091/00020856
http://hdl.handle.net/10091/00020856
3115ca25-6e22-4ed3-a858-77ecb6ccb517
名前 / ファイル ライセンス アクション
25460167_03.pdf 25460167_03.pdf (738.6 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2018-09-13
タイトル
タイトル In Vitro Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod: Possible Mechanism of Iguratimod-Warfarin Interaction
言語
言語 eng
DOI
関連識別子 https://doi.org/10.1248/bpb.b14-00711
関連名称 10.1248/bpb.b14-00711
キーワード
主題 iguratimod, warfarin, CYP2C9, inhibition, drug–drug interaction, polymorphism
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ journal article
著者 Yamaori, S

× Yamaori, S

en Yamaori, S

Search repository
Takami, K

× Takami, K

en Takami, K

Search repository
Shiozawa, A

× Shiozawa, A

en Shiozawa, A

Search repository
Sakuyama, K

× Sakuyama, K

en Sakuyama, K

Search repository
Matsuzawa, N

× Matsuzawa, N

en Matsuzawa, N

Search repository
Ohmori, S

× Ohmori, S

en Ohmori, S

Search repository
信州大学研究者総覧へのリンク
氏名 Yamaori, Satoshi
URL https://soar-rd.shinshu-u.ac.jp/profile/ja.jefNgUkh.html
出版者
出版者 PHARMACEUTICAL SOC JAPAN
引用
内容記述 BIOLOGICAL & PHARMACEUTICAL BULLETIN.38(3):441-447(2015)
書誌情報 BIOLOGICAL & PHARMACEUTICAL BULLETIN

巻 38, 号 3, p. 441-447, 発行日 2015-03-01
抄録
内容記述 Iguratimod is a novel disease-modifying antirheumatic drug. A blue letter (safety advisory) for drug interaction between iguratimod and warfarin was issued by the Ministry of Health, Labour and Welfare of Japan in May 2013. Iguratimod may affect warfarin metabolism catalyzed by CYP. However, it is not clear whether iguratimod inhibits warfarin oxidation. This study was performed to investigate the effects of iguratimod on warfarin 7-hydroxylation with human liver microsomes (HLMs) and recombinant CYP enzymes. Iguratimod concentration-dependently inhibited R,S-warfarin 7-hydroxylase activity of HLMs with an IC50 value of 15.2 µM. The inhibitory effect was examined with S-warfarin and R-warfarin to determine which enantiomer was more potently inhibited by iguratimod. Iguratimod potently inhibited the S-warfarin 7-hydroxylase activity of HLMs with an IC50 value of 14.1 µM, but showed only slight inhibition of R-warfarin 7-hydroxylation. Furthermore, iguratimod inhibited the S-warfarin 7-hydroxylase activity of recombinant CYP2C9.1 (rCYP2C9.1) and rCYP2C9.3 in a concentration-dependent manner with IC50 values of 10.8 and 20.1 µM, respectively. Kinetic analysis of the inhibition of S-warfarin 7-hydroxylation by iguratimod indicated competitive-type inhibition for HLMs and rCYP2C9.1 but mixed-type inhibition for rCYP2C9.3. The Ki values for HLMs, rCYP2C9.1, and rCYP2C9.3 were 6.74, 4.23, and 14.2 µM, respectively. Iguratimod did not exert metabolism-dependent inhibition of S-warfarin 7-hydroxylation. These results indicated that iguratimod is a potent direct inhibitor of CYP2C9-mediated warfarin 7-hydroxylation and that its inhibitory effect on CYP2C9.1 was more sensitive than that on CYP2C9.3.
資源タイプ(コンテンツの種類)
ISSN
収録物識別子タイプ PISSN
収録物識別子 0918-6158
書誌レコードID
収録物識別子タイプ NCID
収録物識別子 AA11696048
PubMed
識別子タイプ PMID
関連識別子 https://www.ncbi.nlm.nih.gov/pubmed/25757926
関連名称 25757926
権利
権利情報 © 2015 The Pharmaceutical Society of Japan
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
WoS
URL http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000350092300013
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 08:15:10.195239
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3